- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Advancing Hematologic Care and the Future of Shared Decision-Making
Sikander Ailawadhi, MD, discusses how the studies presented at ASH 2024 highlight significant unmet needs in hematologic cancer management, emphasizing the potential for these findings to influence future clinical practices and shared decision-making models, while identifying key areas for further research and collaboration to improve patient outcomes.
EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024
EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making
EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
EP: 4.Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
EP: 5.Advancing Hematologic Care and the Future of Shared Decision-Making
Video content above is prompted by the following:
- In what ways do these studies’ data collectively advance our understanding of unmet needs in hematologic cancer management, and how can their findings shape future clinical practices?
- How can the findings presented at ASH 2024 shape the next generation of shared decision-making models for patients with hematologic cancers?
- What are some key areas where you think further research and collaboration are needed to continue improving patient outcomes?
Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL
July 7th 2025Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) treated with venetoclax plus obinutuzumab experienced significantly higher rates of serious infections compared with those receiving zanubrutinib, according to real-world data.
Read More
MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL
June 30th 2025Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.
Read More
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy
June 26th 2025Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.
Read More
